Interferon Beta-1a Inhalation Solution SNG001 clinical trials
How each study uses Interferon Beta-1a Inhalation Solution SNG001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Synairgen Research Ltd. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Interferon beta-1a (4) · Bamlanivimab (1) · Amubarvimab (1) · Romlusevimab (1) · Cilgavimab and tixagevimab drug combination (1) · Camostat (1) · Ogalvibart (1) · Crexavibart (1)
Studies
Open first, then newest update. How each study uses Interferon Beta-1a Inhalation Solution SNG001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral InfectionTerminatedPhase 2Synairgen Research Ltd.NCT06999603Written as SNG001
- ACTIV-2: A Study for Outpatients With COVID-19CompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT04518410Written as SNG001
- Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19CompletedPhase 3Synairgen Research Ltd.NCT04732949Written as SNG001
- Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) InfectionCompletedPhase 2Synairgen Research Ltd.NCT04385095Written as SNG001